DxTerity

COVID-19 Neutralizing Antibody Test

DxTerity Diagnostics Inc. 19500 South Rancho Way, Suite 116 Rancho Dominguez, CA 90220

> Contact us: (424) 758-0100 Email: lab@dxterity.com

Neutralizing Antibody Results



TEST NAME RESULT VALUE

Neutralizing Antibody Test Positive 25,000U/ml

Anti-SARS-CoV-2 Competitive Viral Neutralization Test (cVNT): A Blocking Enzyme-Linked Immunosorbent Assay (ELISA) intended for the semi-quantitative detection of total neutralizing antibodies to SARS-CoV-2 (COVID-19).¹

- 1. This test is intended as an aid in identifying individuals with an adaptive immune response to COVID-19, indicating recent or prior infection. This semiquantitative COVID-19 cVNT antibody test provides a positive or negative result and a numerical value that can show your immune response over time if you use the same test.
- 2. A Neutralizing Antibody (NAb) is an antibody that is responsible for defending cells from pathogens, which are microorganisms that cause infection. They are produced naturally by the body as part of its immune response, and their production is triggered by both infections and vaccinations against infection.²
- 3. SARS-CoV-2 Neutralizing Antibodies have been shown to be predictive of immune protection against symptomatic SARS-CoV-2 infection.³⁻⁵
- 4. Individuals with COVID-19 immune response from vaccination or infection may still have significant immunity in the absence of detectable neutralizing antibodies.3

ORDERING PHYSICIAN SPECIMEN INFORMATION PATIENT INFORMATION Dr. John Smith Specimen Type: Blood Jane Q. Sample Name 1234567 P000001139 Date of Birth: 05 | 22 | 2022 NPI# Accession #: Address: 123 Sampleton Road 05 | 22 | 2022 Patient ID/MRN: 483474 Collection Date: Suite 101, Sampleton, CA 95959 Female Accession Date: 05 | 22 | 2022 Gender: CPT Codes: 000XX1 Report Date: 22 2022 Requisition #: 2948376

Disclaimer: This test was developed, and its performance characteristics determined by DxTerity Diagnostics in a manner consistent with CLIA requirements. It has not been cleared or approved by the U.S. Food and Drug Administration. The information contained in this report is intended to be interpreted by a licensed physician or other licensed healthcare professional. This report is not intended to take the place of professional medical advice. Decisions regarding course of medical treatment must be made only after consulting with a licensed physician or other licensed healthcare professional and should consider each patient's medical history. Validation was performed by DxTerity Diagnostics Inc. CLIA # 05D2054007 on an open automated ELISA system.

References:

- 1. Tan C.W. et al A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE-2-spike protein-protein interaction. Nat. Biotechnol. (2020)
- 2. https://www.news-medical.net/health/What-are-Neutralizing-Antibodies.aspx
- 3. Khoury DS, Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection, Nat Med (2021). https://doi.org/10.1038/s41591-021-01377-8
- 4. DxTerity White Paper SARS-CoV-2 Neutralizing Antibody Levels Provide Estimate of COVID-19 Protection Following Vaccination or Infection. DxTerity Data on File
- 5. Abedi MR, et al. 2021. Predicting COVID-19 Vaccine Efficacy from Neutralizing Antibody Levels. medRxiv reprint 2021.10.13.21264921; doi: https://doi.org/10.1101/2021.10.13.21264921



DxTerity

COVID-19 Neutralizing Antibody Test

DxTerity Diagnostics Inc. 19500 South Rancho Way, Suite 116 Rancho Dominguez, CA 90220

> Contact us: (424) 758-0100 Email: lab@dxterity.com

TEST NAME RESULT VALUE

Neutralizing Antibody Test

Below Limit of Detection

Anti-SARS-CoV-2 Competitive Viral Neutralization Test (cVNT): A Blocking Enzyme-Linked Immunosorbent Assay (ELISA) intended for the semi-quantitative detection of total neutralizing antibodies to SARS-CoV-2 (COVID-19).¹

- This test is intended as an aid in identifying individuals with an adaptive immune response to COVID-19, indicating recent or prior infection. This semiquantitative COVID-19 cVNT antibody test provides a positive or negative result and a numerical value that can show your immune response over time if you use the same test.
- 2. A Neutralizing Antibody (NAb) is an antibody that is responsible for defending cells from pathogens, which are microorganisms that cause infection. They are produced naturally by the body as part of its immune response, and their production is triggered by both infections and vaccinations against infection.²
- 3. SARS-CoV-2 Neutralizing Antibodies have been shown to be predictive of immune protection against symptomatic SARS-CoV-2 infection.³⁻⁵
- 4. Individuals with COVID-19 immune response from vaccination or infection may still have significant immunity in the absence of detectable neutralizing antibodies.³

ORDERING PHYSICIAN SPECIMEN INFORMATION PATIENT INFORMATION Name: Dr. John Smith Specimen Type: Blood Jane Q. Sample 1234567 P000001139 Date of Birth: 05 | 22 | 2022 NPI#: Accession #: Address: 123 Sampleton Road Collection Date: 22 2022 Patient ID/MRN: 483474 Suite 101, Sampleton, CA 95959 22 2022 Female Accession Date: 05 Gender CPT Codes: 000XX1 Report Date: 05 22 2022 Requisition #: 2948376

Disclaimer: This test was developed, and its performance characteristics determined by DxTerity Diagnostics in a manner consistent with CLIA requirements. It has not been cleared or approved by the U.S. Food and Drug Administration. The information contained in this report is intended to be interpreted by a licensed physician or other licensed healthcare professional. This report is not intended to take the place of professional medical advice. Decisions regarding course of medical treatment must be made only after consulting with a licensed physician or other licensed healthcare professional and should consider each patient's medical history. Validation was performed by DxTerity Diagnostics Inc. CLIA # 05D2054007 on an open automated ELISA system.

References:

- 1. Tan C.W. et al A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE-2-spike protein-protein interaction. Nat. Biotechnol. (2020)
- 2. https://www.news-medical.net/health/What-are-Neutralizing-Antibodies.aspx
- 3. Khoury DS, Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection, Nat Med (2021). https://doi.org/10.1038/s41591-021-01377-8
- 4. DxTerity White Paper SARS-CoV-2 Neutralizing Antibody Levels Provide Estimate of COVID-19 Protection Following Vaccination or Infection. DxTerity Data on File
- 5. Abedi MR, et al. 2021. Predicting COVID-19 Vaccine Efficacy from Neutralizing Antibody Levels. medRxiv reprint 2021.10.13.21264921; doi: https://doi.org/10.1101/2021.10.13.21264921



DxTerity

COVID-19 Neutralizing Antibody Test

DxTerity Diagnostics Inc. 19500 South Rancho Way, Suite 116 Rancho Dominguez, CA 90220

> Contact us: (424) 758-0100 Email: lab@dxterity.com

Neutralizing Antibody Results



TEST NAME RESULT VALUE

Neutralizing Antibody Test Negative Below Limit of Detection

Anti-SARS-CoV-2 Competitive Viral Neutralization Test (cVNT): A Blocking Enzyme-Linked Immunosorbent Assay (ELISA) intended for the semi-quantitative detection of total neutralizing antibodies to SARS-CoV-2 (COVID-19).¹

- This test is intended as an aid in identifying individuals with an adaptive immune response to COVID-19, indicating recent or prior infection. This semiquantitative COVID-19 cVNT antibody test provides a positive or negative result and a numerical value that can show your immune response over time if you use the same test.
- 2. A Neutralizing Antibody (NAb) is an antibody that is responsible for defending cells from pathogens, which are microorganisms that cause infection. They are produced naturally by the body as part of its immune response, and their production is triggered by both infections and vaccinations against infection.²
- 3. SARS-CoV-2 Neutralizing Antibodies have been shown to be predictive of immune protection against symptomatic SARS-CoV-2 infection.³⁻⁵
- 4. Individuals with COVID-19 immune response from vaccination or infection may still have significant immunity in the absence of detectable neutralizing antibodies.3

ORDERING PHYSICIAN SPECIMEN INFORMATION PATIENT INFORMATION Name: Dr. John Smith Specimen Type: Blood Jane Q. Sample 1234567 P000001139 Date of Birth: 05 | 22 | 2022 NPI# Accession #: Address: 123 Sampleton Road Collection Date: 22 2022 Patient ID/MRN: 483474 Suite 101, Sampleton, CA 95959 22 2022 Female 05 Gender Accession Date: CPT Codes: 000XX1 Report Date: 05 22 2022 Requisition #: 2948376

Disclaimer: This test was developed, and its performance characteristics determined by DxTerity Diagnostics in a manner consistent with CLIA requirements. It has not been cleared or approved by the U.S. Food and Drug Administration. The information contained in this report is intended to be interpreted by a licensed physician or other licensed healthcare professional. This report is not intended to take the place of professional medical advice. Decisions regarding course of medical treatment must be made only after consulting with a licensed physician or other licensed healthcare professional and should consider each patient's medical history. Validation was performed by DxTerity Diagnostics Inc. CLIA # 05D2054007 on an open automated ELISA system.

References:

- 1. Tan C.W. et al A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE-2-spike protein-protein interaction. Nat. Biotechnol. (2020)
- 2. https://www.news-medical.net/health/What-are-Neutralizing-Antibodies.aspx
- 3. Khoury DS, Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection, Nat Med (2021). https://doi.org/10.1038/s41591-021-01377-8
- 4. DxTerity White Paper SARS-CoV-2 Neutralizing Antibody Levels Provide Estimate of COVID-19 Protection Following Vaccination or Infection. DxTerity Data on File
- 5. Abedi MR, et al. 2021. Predicting COVID-19 Vaccine Efficacy from Neutralizing Antibody Levels. medRxiv reprint 2021.10.13.21264921; doi: https://doi.org/10.1101/2021.10.13.21264921

